Presented at the All-Island Cancer Summit, the Cancer Dashboard for Ireland report outlines growing pressures on Ireland’s cancer system and identifies key priorities for the next National Cancer Strategy.
The European Commission has approved AKEEGA® (niraparib and abiraterone acetate) for patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, following Phase 3 data showing a significant delay in disease progression and an early survival benefit.
The Irish Cancer Society provided almost 30,000 free lifts to and from cancer treatment in 2025, alongside thousands of counselling sessions, support line conversations, and nights of end-of-life nursing care, according to new figures released ahead of Daffodil Day.
